New FINTEPLA® (Fenfluramine) Data Show Long-Term Seizure Frequency Reductions in Patients with Lennox-Gastaut Syndrome (LGS)

Median reduction in drop seizure frequency was 39.4% at 3 months (n= 227; p<0.0001) and 51.8% for patients assessed over months 10 to 12 (n=170; p<0.0001). A Supplemental New Drug Application (sNDA) was recently submitted seeking FDA approval for the u